Tekla Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Tekla Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$12.4M	Buy	138,791 +15,000	+12%	+$1.31M	0.48%	50
2023 Q1	$13.3M	Hold	123,791	–	–	0.51%	45
2022 Q4	$15.1M	Buy	123,791 +55,997	+83%	+$6.5M	0.57%	43
2022 Q3	$7M	Hold	67,794	–	–	0.29%	64
2022 Q2	$6.3M	Hold	67,794	–	–	0.25%	78
2022 Q1	$7.96M	Hold	67,794	–	–	0.28%	73
2021 Q4	$9.12M	Hold	67,794	–	–	0.29%	76
2021 Q3	$10.8M	Sell	67,794 -85,842	-56%	-$11.7M	0.35%	71
2021 Q2	$20.2M	Buy	153,636 +35,300	+30%	+$4.7M	0.66%	42
2021 Q1	$15.3M	Buy	118,336 +22,090	+23%	+$3.36M	0.52%	52
2020 Q4	$16.1M	Sell	96,246 -29,500	-23%	-$4.88M	0.56%	51
2020 Q3	$19.4M	Buy	125,746 +68,264	+119%	+$9.81M	0.73%	34
2020 Q2	$8.5M	Sell	57,482 -11,850	-17%	-$1.63M	0.32%	65
2020 Q1	$7.81M	Hold	69,332	–	–	0.35%	58
2019 Q4	$9.64M	Sell	69,332 -7,835	-10%	-$870K	0.36%	61
2019 Q3	$7.43M	Buy	77,167 +3,520	+5%	+$393K	0.32%	62
2019 Q2	$8.48M	Buy	73,647 +12,287	+20%	+$1.47M	0.35%	66
2019 Q1	$7.22M	Buy	61,360 +18,961	+45%	+$1.66M	0.29%	73
2018 Q4	$2.66M	Sell	42,399 -23,315	-35%	-$1.46M	0.11%	115
2018 Q3	$4.66M	Buy	65,714 +21,800	+50%	+$1.5M	0.17%	97
2018 Q2	$2.92M	Buy	43,914 +37,700	+607%	+$2.48M	0.11%	118
2018 Q1	$406K	Buy	+6,214	New	+$349K	0.02%	176

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Tekla Capital Management's ASND Position: Q2 2023 in Review

Tekla Capital Management increased its Ascendis Pharma A/S (ASND) stake by 12% in Q2 2023, buying an estimated $1.31M and bringing the position to 138,791 shares worth $12.4M. The position accounts for 0.48% of the portfolio, ranked #50.

Tekla Capital Management first reported a position in ASND in Q1 2018 and has held it in 22 quarters since. The position peaked at $20.2M in Q2 2021. 158 funds tracked by Wall St. Rank hold ASND as of Q2 2023.

Tekla Capital Management held 138,791 shares of Ascendis Pharma A/S worth $12.4M as of Q2 2023.
Tekla Capital Management bought 15,000 Ascendis Pharma A/S shares in Q2 2023, an estimated $1.31M.
Ascendis Pharma A/S made up 0.48% of Tekla Capital Management's portfolio in Q2 2023, its #50 holding.
Tekla Capital Management first reported a position in Ascendis Pharma A/S in Q1 2018 and has held it in 22 quarters since.
Tekla Capital Management's Ascendis Pharma A/S position peaked at $20.2M in Q2 2021.
158 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.